Today's top medical abstracts
Endocrinology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Endocrinology
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Endocrinology
        Adrenal Glands
        Atherosclerosis/Lipids
        Basic Science/Genetics
        Bone Metabolism
        Diabetes
        Diagnostics
        Economics of Medicine
        Endocrine Oncology
        Fetal Development
        Hypertension
        Metabolism and Growth
        Neuroendocrinology
        Obesity
        Pediatric Endocrinology
        Pharmacology/kinetics
        Popular Press
        Primary Care
        Reproductive
    Endocrinology
        Thyroid/Parathyroid
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
FDA Update: Thyrotropin Approved For Thyroid Cancer Ablation
Tracy Hampton, PhD, MDLinx Oncology
  See all
low vitamin D status;rapid correction Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Rapid correction of low vitamin D status in nursing home residents
Osteoporosis International, 06/20/08
Print     Email This Article     Save in My Library   Free Abstract
Przybelski R et al. – This prospective study finds that ergocalciferol 50,000 IU three times weekly for four weeks effectively and safely corrects vitamin D inadequacy in nursing home residents.

Methods
  • Study to evaluate the efficacy and safety of short course, high dose, oral vitamin D2 (ergocalciferol) treatment
  • 63 nursing home residents were enrolled
  • The 25 with low vitamin D status received oral ergocalciferol 50,000 IU x3 weekly for 4 wks; the others received no change to their routine care
  • Serum total 25(OH)D, 25(OH)D2, 25(OH)D3, calcium, parathyroid hormone (PTH), bone turnover markers and neuro-cognitive assessments were obtained at baseline and 4 wks

Results
  • Mean total 25(OH)D concentration increased from 17.3 to 63.8 ng/ml in the treated group and remained unchanged in the comparison group
  • Serum 25(OH)D3 remained stable in the comparison group, but declined with D2 treatment from 15.4 to 9.1 ng/ml
  • Serum PTH trended down in the treatment group
  • No treatment-induced improvement in ambulation, cognition or behavior was observed
  • No hypercalcemia or other adverse effects were observed with ergocalciferol treatment

Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.